Saltar al contenido
Merck

7SL RNA represses p53 translation by competing with HuR.

Nucleic acids research (2014-08-16)
Kotb Abdelmohsen, Amaresh C Panda, Min-Ju Kang, Rong Guo, Jiyoung Kim, Ioannis Grammatikakis, Je-Hyun Yoon, Dawood B Dudekula, Ji Heon Noh, Xiaoling Yang, Jennifer L Martindale, Myriam Gorospe
RESUMEN

Noncoding RNAs (ncRNAs) and RNA-binding proteins are potent post-transcriptional regulators of gene expression. The ncRNA 7SL is upregulated in cancer cells, but its impact upon the phenotype of cancer cells is unknown. Here, we present evidence that 7SL forms a partial hybrid with the 3'-untranslated region (UTR) of TP53 mRNA, which encodes the tumor suppressor p53. The interaction of 7SL with TP53 mRNA reduced p53 translation, as determined by analyzing p53 expression levels, nascent p53 translation and TP53 mRNA association with polysomes. Silencing 7SL led to increased binding of HuR to TP53 mRNA, an interaction that led to the promotion of p53 translation and increased p53 abundance. We propose that the competition between 7SL and HuR for binding to TP53 3'UTR contributes to determining the magnitude of p53 translation, in turn affecting p53 levels and the growth-suppressive function of p53. Our findings suggest that targeting 7SL may be effective in the treatment of cancers with reduced p53 levels.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Cicloheximida, from microbial, ≥94% (TLC)
Sigma-Aldrich
Cycloheximide solution, Ready-Made Solution, microbial, 100 mg/mL in DMSO, Suitable for cell culture
Sigma-Aldrich
Cycloheximide, ≥90% (HPLC)
Sigma-Aldrich
Cicloheximida, Biotechnology Performance Certified
Millipore
Cycloheximide solution, 0.1%, suitable for microbiology
Supelco
Cicloheximida, PESTANAL®, analytical standard
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Elavl1
Sigma-Aldrich
MISSION® esiRNA, targeting human ELAVL1